An updated edition of the Jan. 6, 2026, article.Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics primarily ai ...

MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (FIL), Lisbon ...

Core Insights - Oryzon Genomics has appointed Dr. Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS Programs, bringing over 20 years of experience in neuroscience and psychiatry drug development [1][2][3] - Dr. Gutierrez-Esteinou will lead the Phase III clinical development of vafidemstat, targeting agitation and aggression in borderline personality disorder, while also expanding its use in autism spectrum disorder and schizophrenia [2][4] - Oryzon is recognized as a leader in epigenetics, focusing on personalized medicine for CNS disorders and oncology, with a clinical portfolio that includes two LSD1 inhibitors [5][6] Company Overview - Oryzon Genomics, founded in 2000 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics [5] - The company has a strong clinical portfolio, including vafidemstat, which is Phase III-ready, and iadademstat, which is in ongoing Phase I and II studies with promising results in acute myeloid leukemia [5][6] - Oryzon is advancing a broader epigenetics pipeline, including a clinical candidate for Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis [6]

Core Insights - Interpace Biosciences reported preliminary 2025 thyroid testing revenue growth of 21% compared to the previous year, with total revenue estimated at approximately $38-39 million, of which $34-35 million is attributed to thyroid testing [3][4] - The company has initiated guidance for 2026, projecting a revenue of approximately $40 million, representing a 16% growth in thyroid testing revenue over 2025 [4] - All preferred stock has been converted to common stock, simplifying the capital structure and resulting in approximately 27.7 million shares outstanding [5][6] - Interpace has a debt-free balance sheet and is operating with positive net income and EBITDA [7] - The company plans to seek an uplisting on the Nasdaq Stock Market in 2026, aiming to attract more investors and facilitate growth [7][8] Revenue Performance - Preliminary 2025 revenue from continuing operations is approximately $38-39 million, with thyroid testing contributing around $34-35 million [3] - The growth in thyroid testing revenue is approximately 21% over 2024 [3] - For 2026, the company anticipates revenue of about $40 million, with 100% derived from thyroid testing, indicating a projected growth of 16% [4] Capital Structure - In October 2024, all Series C Preferred shares were converted into common stock, resulting in the issuance of approximately 23,267,327 shares [5] - Following the conversion, the total pro forma basic shares outstanding is approximately 27.7 million [6] - Major shareholders include 1315 Capital with approximately 34% and Ampersand with about 50% of the outstanding common stock [6] Strategic Plans - The conversion of preferred stock and the elimination of debt are seen as pivotal milestones in the company's capital structure [7] - The company aims to leverage its simplified capital structure to focus on scaling its profitable thyroid diagnostics business [7] - Plans for uplisting to the Nasdaq are intended to enhance investor participation and support growth initiatives in sales and research [8]

Market Overview - The RNA therapy market is projected to grow from USD 18.77 billion in 2025 to USD 19.70 billion in 2026, with a compound annual growth rate (CAGR) of 6.40%, reaching USD 28.99 billion by 2032, driven by clinical proof, supply chain improvements, and regional investments [1][6]. Therapeutic Applications - RNA-based therapeutics are applicable in various therapeutic areas, including cardiovascular diseases, genetic disorders, infectious diseases, metabolic and neurological diseases, oncology (hematological cancers and solid tumors), and rare conditions like Gaucher disease and sickle cell disease, broadening the market scope [4]. Delivery Platforms - Delivery platforms for RNA therapies include exosomes, lipid nanoparticles, polymer carriers, and viral vectors, which influence targeting ability, immune response, production scale, and clinical trial timelines, allowing developers to customize delivery methods [4]. End-User Groups - The end-user groups for RNA therapies consist of biotechnology companies, pharmaceutical manufacturers, hospitals, clinics, and research institutes, shaping commercialization strategies and market entry timings [4]. Geographic Regions - The RNA therapy market spans the Americas, Europe, the Middle East & Africa, and Asia-Pacific, each presenting unique regulatory challenges, adoption rates, and infrastructure capabilities, necessitating navigation of regional nuances [4]. Strategic Considerations - Successful RNA therapy development relies on scientific innovation, delivery platform selection, supply chain resilience, and partnerships with healthcare institutions, with strategic distinction depending on aligning delivery technologies with pipeline priorities [4][9]. Industry Collaboration - Collaborative efforts between biotech firms and established pharmaceutical companies are accelerating clinical adoption and easing operational and regulatory integration, responding to heightened end-user demands for rapid production cycles and targeted therapies [9]. Market Insights - The report provides prioritized insights on RNA therapy pipelines and delivery technologies, aiding in adapting regulatory and supply chain strategies to shifting policies and supporting global operational flexibility [9].

Labcorp FY Conference Summary Company Overview - **Company**: Labcorp (NYSE: LH) - **Date of Conference**: January 13, 2026 Key Industry Insights - **Core Therapeutic Areas**: Labcorp is focusing on four core therapeutic areas: oncology, women's health, autoimmune, and neurology, which are expected to grow two to three times faster than the overall diagnostic market [5][6] - **M&A Activity**: In 2025, Labcorp announced 13 new or closed deals, enhancing growth opportunities [5] - **AI Integration**: Significant advancements in artificial intelligence and automation in laboratories, particularly in cytology and microbiology, were highlighted [6][32] Financial Performance - **2025 Performance**: Labcorp reported solid core fundamentals and improved organic growth, with a target of 4.5% organic revenue growth for the full year [13] - **Integration Success**: The integration of Invitae was noted as a remarkable achievement, turning a struggling company into an accretive business by Q3 2025 [7][10] - **Volume Impact from ACA Changes**: An estimated 30 basis points of volume impact on the diagnostic business in 2026 due to ACA subsidy expirations was discussed [20] Growth Drivers - **Increased Testing Utilization**: The aging population and a rise in chronic illnesses are driving increased testing utilization, which is expected to remain higher than pre-COVID levels [14][15] - **Specialty Testing Growth**: Labcorp anticipates growth in specialty testing, particularly in oncology, neurology, and autoimmune diseases, which are expected to drive higher test volumes [22][23] - **Managed Care Relationships**: Strong relationships with managed care organizations are expected to facilitate better pricing negotiations and increased volume [49] Challenges and Risks - **PAMA Legislation**: The potential impact of PAMA on pricing and diagnostics was discussed, with a cautious optimism regarding delays in its implementation [54][58] - **Biopharma Lab Services**: The early development segment is facing challenges due to funding and interest rates, leading to a focus on profitability and divestiture of non-core areas [64][65] Future Outlook - **Capital Deployment Strategy**: Labcorp plans to continue investing in capital expenditures, focusing on technology and infrastructure improvements [43][44] - **Tailwinds for 2026**: Anticipated strong underlying utilization trends, specialty testing growth, and M&A activities are expected to drive growth in 2026 [74] - **AI and Automation**: Continued focus on AI and automation is expected to enhance operational efficiency and reduce costs [73] Additional Insights - **Consumer Health Trends**: Increased consumer focus on health and wellness is seen as an opportunity for Labcorp's OnDemand services, which offer a variety of tests [51][52] - **Companion Diagnostics**: The importance of companion diagnostics in personalized medicine is emphasized as a way to reduce healthcare costs and improve patient outcomes [30][31] This summary encapsulates the key points discussed during the Labcorp FY conference, highlighting the company's strategic focus, financial performance, growth drivers, challenges, and future outlook.

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a leader in epigenetics and focuses on personalized medicine for CNS disorders and oncology [3] Group 1: Upcoming Events - Oryzon management will participate in the 9th Sachs Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, with a presentation scheduled at 10:35 am (PST) [1] - The company will also attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, and the Allinvest Securities Biomed Forum on January 29, 2026, in Paris, where one-on-one meetings will be available [2] Group 2: Company Overview - Founded in 2000 in Barcelona, Oryzon is recognized as the European leader in epigenetics, with a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) for CNS and iadademstat (Phase II) for oncology/hematology [3] - The company is developing other pipeline assets targeting epigenetic mechanisms, including ORY-4001 for potential use in CMT and ALS, and has a robust platform for biomarker identification and target validation across various malignant and neurological diseases [3]

Industry Overview - Genomics is a comprehensive study of genomes, which has gained significant interest from pharmaceutical and biotechnology companies for understanding diseases and developing therapies [2] - The distinction between genetics and genomics is crucial, with genomics focusing on the complete set of genes and their interactions within an organism [3] - Insights from genomic research are increasingly utilized to evaluate patient responses to drugs and support the development of targeted therapies, advancing personalized medicine [4] - The growth of genomics has also bolstered synthetic biology, which applies engineering principles to biology for various applications, including drug discovery and gene editing [5] - The rapid advancements in genomics are driven by significant reductions in the cost and time required for genome sequencing [6] Market Projections - The genomics market is projected to reach $80.17 billion by 2032 [9] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to grow at a CAGR of 17.7% from 2026 to 2033 [9] Key Companies - **Pacific Biosciences of California (PACB)**: Specializes in advanced long-read sequencing systems for various applications, including healthcare and agriculture. The company has a Zacks Rank 2 (Buy) [12][14] - **Wave Life Sciences (WVE)**: A clinical-stage biotechnology company focusing on RNA medicines. The company reported positive interim data for its obesity treatment candidate WVE-007, which showed improvements in body composition [15][17] - **Sana Biotechnology (SANA)**: Developing cell engineering platforms for diseases like type 1 diabetes and B-cell cancers. The company has suspended its CAR T programs to focus on more promising candidates and has a Zacks Rank 3 [19][21]

Core Insights - Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has set a national Medicare payment rate of $300 for its inFoods® IBS test, effective January 1, 2026, under the Clinical Laboratory Fee Schedule (CLFS) [1][9] - The establishment of a dedicated CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, effective October 1, 2025, enhances the test's market position and patient access [2] Commercial Milestone - The $300 payment rate from CMS provides a foundation for negotiations with private insurers, as CMS is the largest payer in the U.S. healthcare system, accounting for approximately 21% of total healthcare expenditure [3][9] - The CEO of Biomerica emphasized that the pricing determination is a significant milestone for both the company and patients suffering from IBS, positioning the company for commercial growth in 2026 and beyond [4] Market Need - Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the U.S., translating to over 30 million potential patients, highlighting a significant unmet medical need [4] - Current treatment options for IBS often provide inconsistent relief and may involve side effects, with no FDA-approved drugs for the IBS-M subtype, which represents about one-third of the IBS market [4] Product Efficacy - The inFoods® IBS test utilizes a personalized diagnostic approach to identify food triggers for IBS symptoms, allowing for targeted dietary recommendations [5] - Clinical trials demonstrated that 59.6% of patients who eliminated identified trigger foods met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group [6] - Notable efficacy was observed in difficult-to-treat populations, with 67.1% of IBS-C patients and 66% of IBS-M patients achieving FDA-target pain reduction [7] Strategic Positioning - The combination of clinical evidence, a dedicated PLA code, and a national CLFS price represents a pivotal moment for inFoods® IBS [8] - The company plans to work with Medicare Administrative Contractors to secure coverage for the inFoods® IBS test and leverage the established pricing to negotiate with private insurers [10] Value Proposition - The CMS pricing announcement enhances Biomerica's market opportunity by providing a differentiated offering, a large patient population, a personalized medicine approach, and platform potential for additional gastrointestinal conditions [11]

Core Viewpoint - Viewbix Inc. is set to acquire Quantum X Labs, which has developed a groundbreaking quantum computing technology that enhances clinical trial methodologies, potentially transforming the pharmaceutical and drug discovery markets [4][5]. Group 1: Acquisition Details - Viewbix has signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, which includes its expanding patent portfolio [5]. - The acquisition is expected to close within 90 days from December 15, 2025, pending due diligence and regulatory approvals [5]. Group 2: Technological Advancements - Quantum X Labs has filed a provisional patent for a technology that improves Markov Chain Monte Carlo methods using quantum computing, allowing for more efficient sampling from complex probability distributions [2]. - The new methodology aims to reveal hidden biological structures and dependencies in clinical data, enabling better identification of patient clusters and treatment responses with potentially fewer samples than traditional methods [3]. Group 3: Market Implications - The advancements from Quantum X Labs could convert underpowered clinical trial datasets into robust mechanistic evidence, enhancing the success rates of personalized medicine [4]. - As quantum computing technology matures, it positions Viewbix to capture significant value in the pharmaceutical sector by reducing trial costs and timelines [4].